FGFR2 (C491S)

FGFR2 · Variant type: point · HGVS: p.C491S

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Pemigatinib	99.8%	0.2%	98.23
2	Infigratinib	99.1%	0.9%	98.24
3	Erdafitinib	98.0%	2.0%	95.71
4	Brigatinib	97.7%	2.3%	82.96
5	Ripretinib	95.4%	4.6%	92.95
6	Lenvatinib	93.4%	6.6%	97.74
7	Deucravacitinib	93.3%	6.7%	98.99
8	Pazopanib	93.3%	6.7%	97.49
9	Selpercatinib	92.1%	7.9%	96.72
10	Pralsetinib	86.3%	13.7%	93.43
11	Regorafenib	79.0%	21.0%	95.99
12	Ibrutinib	78.0%	22.0%	94.74
13	Tivozanib	75.8%	24.2%	92.42
14	Fostamatinib	75.4%	24.6%	96.74
15	Futibatinib	75.2%	24.8%	98.48
16	Repotrectinib	72.2%	27.9%	84.21
17	Entrectinib	71.6%	28.4%	93.69
18	Vandetanib	71.2%	28.8%	95.74
19	Tepotinib	65.0%	35.0%	99.75
20	Pirtobrutinib	63.5%	36.5%	99.49
21	Fedratinib	61.8%	38.2%	96.21
22	Pacritinib	61.4%	38.6%	88.64
23	Sunitinib	56.3%	43.7%	91.73
24	Defactinib	54.4%	45.6%	92.68
25	Sorafenib	48.4%	51.6%	96.72

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Pemigatinib	99.8%	98.7%	+1.0%
Infigratinib	99.1%	98.8%	+0.3%
Erdafitinib	98.0%	99.0%	-1.0%
Brigatinib	97.7%	96.1%	+1.7%
Ripretinib	95.4%	85.4%	+10.0%
Lenvatinib	93.4%	85.4%	+8.1%
Deucravacitinib	93.3%	92.5%	+0.8%
Pazopanib	93.3%	88.9%	+4.3%
Selpercatinib	92.1%	95.0%	-2.9%
Pralsetinib	86.3%	93.2%	-6.9%
Regorafenib	79.0%	—	—
Ibrutinib	78.0%	—	—
Tivozanib	75.8%	—	—
Fostamatinib	75.4%	—	—
Futibatinib	75.2%	99.3%	-24.1%
Repotrectinib	72.2%	79.8%	-7.7%
Entrectinib	71.6%	81.5%	-9.9%
Vandetanib	71.2%	90.8%	-19.6%
Tepotinib	65.0%	—	—
Pirtobrutinib	63.5%	—	—
Fedratinib	61.8%	—	—
Pacritinib	61.4%	—	—
Sunitinib	56.3%	—	—
Defactinib	54.4%	—	—
Sorafenib	48.4%	—	—

Cancer	Organ	Source
endometrial_carcinoma	Uterus	ref
carcinoma_liver	Liver	ref

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 15.9ms